NOXXON Appoints Experienced Cancer Drug Developer Dr. Jose Saro as Chair of Scientific Advisory Board
01 Febbraio 2021 - 6:00PM
Business Wire
Regulatory News:
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) a
biotechnology company focused on improving cancer treatments by
targeting the tumor microenvironment (TME), announced today the
formation of a Scientific Advisory Board (SAB) and the appointment
of Jose Saro, M.D. as its Chair. Dr. Saro and the SAB will provide
scientific and strategic advice to the company regarding research
and development of its programs in cancer.
“With NOXXON’s focus sharpening onto specific cancers, it is the
right time to form a top-tier advisory board. Dr. Saro brings an
incredibly broad experience in the development of new classes of
anti-cancer agents having worked with multiple immuno-oncology and
tumor-microenvironment targeting agents as well as targeted
therapies at companies including AstraZeneca, Roche, BMS and
Novartis. As an industry expert, he will hold the critical role of
bringing scientific and medical insights from key opinion leaders
into a commercial context. We look forward to announcing the
members of the SAB in the coming weeks. We are delighted to have
him as the leader of our SAB,” commented Aram Mangasarian, CEO
of NOXXON.
Dr. Jose Saro commented: “I am excited to take on the
role of Chair of NOXXON’s Scientific Advisory Board, which will
focus initially on bringing together internationally recognized
experts in pancreatic cancer to advise NOXXON on its upcoming
study. We’ll then add expertise in other areas in a second step. I
am looking forward to accompanying NOXXON’s team as they advance
the company’s clinical programs.”
Dr. Jose Saro brings over 25 years of experience in the
preclinical, translational and clinical development of oncology
compounds to NOXXON. Throughout his career, he has developed an
extensive global network among oncologic academic institutions and
the pharmaceutical industry.
Dr. Saro currently works at AstraZeneca where he leads the
ceralasertib post-PARP inhibitor early clinical development program
in solid tumors. Prior to that, he worked at Avacta as Chief
Medical Officer driving the development strategy of Affimer®
programs into the clinic. Before Avacta, Dr. Saro served as Senior
Translational Medicine Leader at Roche where he ran three global
immunotherapy programs – a targeted cytokine, and two T-cell
bispecific antibodies in solid tumors – in collaboration with top
academic institutions in the EU and US. Previously, he led global
clinical programs at Bristol Myers Squibb including dasatinib,
ipilimumab (anti-CTLA4), nivolumab (anti-PD1), anti-PDL1, anti-KIR,
anti-LAG3, brivanib, a MEK inhibitor, and elotuzumab. While at
Novartis he focused on biomarkers in the preclinical and clinical
settings. Dr. Saro earned a medical degree from the University of
Oviedo, Spain and a master’s degree in pharmaceutical medicine from
Complutense University of Madrid, Spain.
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor
microenvironment (TME) and the cancer immunity cycle by breaking
the tumor protection barrier and blocking tumor repair. By
neutralizing chemokines in the tumor microenvironment, NOXXON’s
approach works in combination with other forms of treatment to
weaken tumor defenses against the immune system and enable greater
therapeutic impact. Building on extensive clinical experience and
safety data, the lead program NOX-A12 has delivered top-line data
from a Keytruda® combination trial in metastatic colorectal and
pancreatic cancer patients and further studies are being planned in
these indications. In September 2019 the company initiated an
additional trial with NOX-A12 in brain cancer in combination with
radiotherapy. The combination of NOX-A12 and radiotherapy has been
granted orphan drug status in the US and EU for the treatment of
certain brain cancers. The company’s second clinical-stage asset
NOX-E36 is a Phase 2 TME asset targeting the innate immune system.
NOXXON plans to test NOX‑E36 in patients with solid tumors both as
a monotherapy and in combination. Further information can be found
at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme
Corp
https://www.linkedin.com/company/noxxon-pharma-ag
https://twitter.com/noxxon_pharma
Disclaimer
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future
results of business segments, financial indicators, developments of
the financial situation or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking
statements as certain prognoses of actual future events and
developments. The company is neither responsible nor liable for
updating such information, which only represents the state of
affairs on the day of publication.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210201005705/en/
NOXXON Pharma N.V. Aram Mangasarian, Ph.D., Chief
Executive Officer Tel. +49 (0) 30 726247 0
amangasarian@noxxon.com
Trophic Communications Gretchen Schweitzer or Valeria
Fisher Tel. +49 (0) 172 861 8540 or +49 (0) 175 804 1816
noxxon@trophic.eu
NewCap Arthur Rouillé Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr